

**Clinical trial results:**

A double-blind, randomised, placebo-controlled clinical study to evaluate the efficacy and safety of N-Acetyl-GED-0507-34-LEVO gel, 1 and 2%, applied once daily for 12 weeks in patients with mild to moderate facial acne vulgaris

Summary

| | |
|--------------------------|-----------------|
| EudraCT number | 2016-000540-33 |
| Trial protocol | HU CZ SK |
| Global end of trial date | 26 January 2017 |

Results information

| | |
|-----------------------------------|---|
| Result version number | v1 (current) |
| This version publication date | 10 June 2022 |
| First version publication date | 10 June 2022 |
| Summary attachment (see zip file) | Clinical Summary Results (Clinical Summary Results_prtoGED0507ACNE0106.pdf) |

Trial information**Trial identification**

| | |
|-----------------------|--------------------|
| Sponsor protocol code | GED-0507-ACN-01-16 |
|-----------------------|--------------------|

Additional study identifiers

| | |
|------------------------------------|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | - |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | PPM SERVICES SA |
| Sponsor organisation address | Viale Serfontana 10, Morbio Inferiore,, Switzerland, 6834 |
| Public contact | Angelo Vaccani, CROSS Reserach, +41 916300510, angelo.vaccani@croalliance.com |
| Scientific contact | Angelo Vaccani, CROSS Reserach, +41 916300510, angelo.vaccani@croalliance.com |
| Sponsor organisation name | PPM Services S.A. |
| Sponsor organisation address | Viale Serfontana 10, Morbio Inferiore, Switzerland, CH-6834 |
| Public contact | Dr Salvatore Bellinvia (Sponsor medical officer), PPM Services S.A., 0041 916969710, sbellinvia@ppmservices.ch |
| Scientific contact | Dr Salvatore Bellinvia (Sponsor medical officer), PPM Services S.A., +41 91 69 61 712, sbellinvia@ppmservices.ch |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No | No |

| | |
|--|----|
| 1901/2006 apply to this trial? | |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|-----------------|
| Analysis stage | Final |
| Date of interim/final analysis | 26 January 2017 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 26 January 2017 |
| Global end of trial reached? | Yes |
| Global end of trial date | 26 January 2017 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

The objective of the study is to evaluate the efficacy and the local and systemic safety of 1% and 2% N-Acetyl-GED-0507-34-Levo gel, in comparison to the matching placebo gel, applied once daily for 12 weeks in patients with mild to moderate facial acne vulgaris

Protection of trial subjects:

Data verification was required and it was performed by direct comparison with source documents, always giving due consideration to data protection and medical confidentiality. In this respect the Investigator have assured support to the monitors at all times.

Background therapy: -

Evidence for comparator: -

| | |
|---|--------------|
| Actual start date of recruitment | 01 July 2016 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|--------------------|
| Country: Number of subjects enrolled | Slovakia: 49 |
| Country: Number of subjects enrolled | Czech Republic: 49 |
| Country: Number of subjects enrolled | Hungary: 49 |
| Worldwide total number of subjects | 147 |
| EEA total number of subjects | 147 |

Notes:

Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |

| | |
|--|-----|
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 18 |
| Adults (18-64 years) | 129 |
| From 65 to 84 years | 0 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

The recruitment took place in the following countries: Hungary, Czech Republic and Slovakia.

Date of first enrolment is 4th July 2016 (first randomized patient)

Date of last completed 26th January 2017 (last visit of the last patient)

Pre-assignment

Screening details:

N. 155 patients have been screened for the study and 147 patients receiving double-blind medication with a total of 6 screening failure patients

Period 1

| | |
|------------------------------|---|
| Period 1 title | overall trial (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator, Monitor, Data analyst, Carer, Assessor |

Arms

| | |
|------------------------------|--------|
| Are arms mutually exclusive? | Yes |
| Arm title | IMP 1% |

Arm description:

N-ACETYL-GED-0507-34-LEVO GEL 1%

| | |
|--|----------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | N-ACETYL-GED-0507-34-LEVO GEL 1% |
| Investigational medicinal product code | N-ACETYL-GED-0507-34-LEVO GEL |
| Other name | |
| Pharmaceutical forms | Gel |
| Routes of administration | Topical use |

Dosage and administration details:

1% daily dosage for 12 weeks

| | |
|------------------|--------|
| Arm title | IMP 2% |
|------------------|--------|

Arm description:

N-ACETYL-GED-0507-34-LEVO GEL 2%

| | |
|--|----------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | N-ACETYL-GED-0507-34-LEVO GEL 2% |
| Investigational medicinal product code | N-ACETYL-GED-0507-34-LEVO GEL |
| Other name | |
| Pharmaceutical forms | Gel |
| Routes of administration | Topical use |

Dosage and administration details:

2% daily dosage for 12 weeks

| | |
|--|-------------|
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | Placebo |
| Other name | |
| Pharmaceutical forms | Gel |
| Routes of administration | Topical use |

Dosage and administration details:

PLACEBO daily for 12 weeks

| | |
|--|-------------|
| Arm title | Placebo |
| Arm description: | |
| Placebo | |
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | Placebo |
| Other name | |
| Pharmaceutical forms | Gel |
| Routes of administration | Topical use |
| Dosage and administration details: | |
| placebo daily use for 12 weeks | |

| Number of subjects in period 1 | IMP 1% | IMP 2% | Placebo |
|---------------------------------------|--------|--------|---------|
| Started | 50 | 50 | 47 |
| Completed | 46 | 50 | 42 |
| Not completed | 4 | 0 | 5 |
| Adverse event, non-fatal | - | - | 1 |
| Progressive Disease | - | - | 1 |
| Withdrawal by Parent/Guardian | 2 | - | - |
| Withdrawal by Subject | 1 | - | 2 |
| Lost to follow-up | - | - | 1 |
| Lack of efficacy | 1 | - | - |

Baseline characteristics

Reporting groups

| | |
|-----------------------|---------------|
| Reporting group title | overall trial |
|-----------------------|---------------|

Reporting group description: -

| Reporting group values | overall trial | Total | |
|--|---------------|-------|--|
| Number of subjects | 147 | 147 | |
| Age categorical | | | |
| Age ranged from 14.0 to 30.0 years. | | | |
| Units: Subjects | | | |
| In utero | 0 | 0 | |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | |
| Newborns (0-27 days) | 0 | 0 | |
| Infants and toddlers (28 days-23 months) | 0 | 0 | |
| Children (2-11 years) | 0 | 0 | |
| Adolescents (12-17 years) | 18 | 18 | |
| Adults (18-64 years) | 129 | 129 | |
| From 65-84 years | 0 | 0 | |
| 85 years and over | 0 | 0 | |
| Age continuous | | | |
| age ranged from 14.0 to 30.0 years. | | | |
| Units: years | | | |
| arithmetic mean | 21.2 | | |
| standard deviation | ± 3.65 | - | |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 85 | 85 | |
| Male | 62 | 62 | |

End points

End points reporting groups

| | |
|----------------------------------|---------|
| Reporting group title | IMP 1% |
| Reporting group description: | |
| N-ACETYL-GED-0507-34-LEVO GEL 1% | |
| Reporting group title | IMP 2% |
| Reporting group description: | |
| N-ACETYL-GED-0507-34-LEVO GEL 2% | |
| Reporting group title | Placebo |
| Reporting group description: | |
| Placebo | |

Primary: Efficacy inflammatory lesions

| | |
|---|-------------------------------|
| End point title | Efficacy inflammatory lesions |
| End point description: | |
| In the whole study period (follow-up included), for all the three analysis sets the inflammatory lesion number showed a decrease over time in the mean value. By considering Intention To Treat Set, after 12 weeks of treatment the percent changes from baseline were -45.2 for N-Acetyl-GED-0507-34-Levo 1% group, -57.2 for 2% and -28.7 for placebo. Results from pairwise two-sided multiple comparison analysis were statistically significant for N-Acetyl-GED-0507-34-Levo 2% vs placebo (p=0.0003) and N-Acetyl-GED-0507-34-Levo 1% vs placebo (p= 0.0329) but not for N-Acetyl-GED-0507-34-Levo 2% vs N-Acetyl-GED-0507-34-Levo 1% (p=0.1085). Similar patterns were observed both in the mITT set and in Sub-Group Analysis N1 Set. | |
| End point type | Primary |
| End point timeframe: | |
| 12 weeks | |

| End point values | IMP 1% | IMP 2% | Placebo | |
|-----------------------------|-----------------|-----------------|-----------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 50 | 50 | 47 | |
| Units: -100-0 | | | | |
| number (not applicable) | -45.2 | -57.2 | -28.7 | |

Statistical analyses

| | |
|--|---------------------------|
| Statistical analysis title | Statistical |
| Statistical analysis description: | |
| The statistical analysis was performed using SAS® version 9.3 – SAS Institute Inc, Cary, NC, USA and carried out according to ICH guidelines ICH E9: "Statistical Principles for Clinical Trials" (CPMP/ICH/363/96 September 1998). All statistical tests were carried out at a significant level (alpha level) of 0.05, two tailed. | |
| Comparison groups | IMP 1% v IMP 2% v Placebo |

| | |
|---|----------------------------|
| Number of subjects included in analysis | 147 |
| Analysis specification | Pre-specified |
| Analysis type | superiority ^[1] |
| P-value | < 0.05 |
| Method | ANCOVA |

Notes:

[1] - In addition to the descriptive analysis, an Ancova model, with baseline value as covariate and treatment as fixed factor was applied to test the null hypothesis H0: "The mean score on the changes from baseline are identical among treatment groups" (both for INF, non-INF, and TOT Les counts). Additional analysis with the ranked change (absolute or percent) in lesion count was performed with an ANCOVA model, by using ranked baseline count as covariate and treatment as factor.

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Overall

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|----|
| Dictionary version | 20 |
|--------------------|----|

Reporting groups

| | |
|-----------------------|-------|
| Reporting group title | TEAEs |
|-----------------------|-------|

Reporting group description: -

| Serious adverse events | TEAEs | | |
|---|-----------------|--|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 2 / 147 (1.36%) | | |
| number of deaths (all causes) | 0 | | |
| number of deaths resulting from adverse events | 0 | | |
| Investigations | | | |
| Laboratory test abnormal | | | |
| subjects affected / exposed | 1 / 147 (0.68%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Pneumothorax spontaneous | | | |
| subjects affected / exposed | 1 / 147 (0.68%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | TEAEs | | |
|---|-------------------|--|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 72 / 147 (48.98%) | | |
| Nervous system disorders | | | |
| Headache | | | |

| | | | |
|---|-------------------------|--|--|
| subjects affected / exposed occurrences (all) | 21 / 147 (14.29%) 21 | | |
| General disorders and administration site conditions APPLICATION SITE DRYNESS subjects affected / exposed occurrences (all) | 19 / 147 (12.93%) 19 | | |
| Application site exfoliation subjects affected / exposed occurrences (all) | 11 / 147 (7.48%) 11 | | |
| Application site erythema subjects affected / exposed occurrences (all) | 11 / 147 (7.48%) 11 | | |
| Gastrointestinal disorders Diarrhoea subjects affected / exposed occurrences (all) | 3 / 147 (2.04%) 3 | | |
| Respiratory, thoracic and mediastinal disorders Oropharyngeal pain subjects affected / exposed occurrences (all) | 4 / 147 (2.72%) 4 | | |
| Skin and subcutaneous tissue disorders Acne subjects affected / exposed occurrences (all) | 7 / 147 (4.76%) 7 | | |
| Infections and infestations Viral upper respiratory tract infection subjects affected / exposed occurrences (all) | 7 / 147 (4.76%) 7 | | |
| Influenza subjects affected / exposed occurrences (all) | 3 / 147 (2.04%) 3 | | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported